These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

82 related articles for article (PubMed ID: 1680897)

  • 1. Immunohistochemical analysis of p53 and HER-2/neu proteins in human tumors.
    Chang K; Ding I; Kern FG; Willingham MC
    J Histochem Cytochem; 1991 Sep; 39(9):1281-7. PubMed ID: 1680897
    [TBL] [Abstract][Full Text] [Related]  

  • 2. P-glycoprotein, HER-2/neu, and mutant p53 expression in human gynecologic tumors.
    Schneider J; Rubio MP; Barbazán MJ; Rodriguez-Escudero FJ; Seizinger BR; Castresana JS
    J Natl Cancer Inst; 1994 Jun; 86(11):850-5. PubMed ID: 7910219
    [TBL] [Abstract][Full Text] [Related]  

  • 3. An immunohistochemical comparison between low-grade and high-grade ovarian serous carcinomas: significantly higher expression of p53, MIB1, BCL2, HER-2/neu, and C-KIT in high-grade neoplasms.
    O'Neill CJ; Deavers MT; Malpica A; Foster H; McCluggage WG
    Am J Surg Pathol; 2005 Aug; 29(8):1034-41. PubMed ID: 16006797
    [TBL] [Abstract][Full Text] [Related]  

  • 4. p53 overexpression in formalin-fixed, paraffin-embedded tissue detected by immunohistochemistry.
    Kerns BJ; Jordan PA; Moore MB; Humphrey PA; Berchuck A; Kohler MF; Bast RC; Iglehart JD; Marks JR
    J Histochem Cytochem; 1992 Jul; 40(7):1047-51. PubMed ID: 1607637
    [TBL] [Abstract][Full Text] [Related]  

  • 5. Relationship of serum levels of tumor markers with tissue expression of gene products in ovarian carcinoma.
    Sorak M; Arsenijević S; Lukić G; Arsenijević N; Ristić P; Pavlović S; Popović S; Baskić D
    J BUON; 2007; 12(1):99-104. PubMed ID: 17436409
    [TBL] [Abstract][Full Text] [Related]  

  • 6. Ovarian adenocarcinomas in the laying hen and women share similar alterations in p53, ras, and HER-2/neu.
    Hakim AA; Barry CP; Barnes HJ; Anderson KE; Petitte J; Whitaker R; Lancaster JM; Wenham RM; Carver DK; Turbov J; Berchuck A; Kopelovich L; Rodriguez GC
    Cancer Prev Res (Phila); 2009 Feb; 2(2):114-21. PubMed ID: 19174584
    [TBL] [Abstract][Full Text] [Related]  

  • 7. HER-2/neu: a differentiation marker in adenocarcinoma of the esophagus.
    Sauter ER; Keller SM; Erner S; Goldberg M
    Cancer Lett; 1993 Nov; 75(1):41-4. PubMed ID: 7904538
    [TBL] [Abstract][Full Text] [Related]  

  • 8. Widespread p53 overexpression in human malignant tumors. An immunohistochemical study using methacarn-fixed, embedded tissue.
    Porter PL; Gown AM; Kramp SG; Coltrera MD
    Am J Pathol; 1992 Jan; 140(1):145-53. PubMed ID: 1731521
    [TBL] [Abstract][Full Text] [Related]  

  • 9. Coexpression of HER-2/neu and p53 is associated with a shorter disease-free survival in node-positive breast cancer patients.
    Wiltschke C; Kindas-Muegge I; Steininger A; Reiner A; Reiner G; Preis PN
    J Cancer Res Clin Oncol; 1994; 120(12):737-42. PubMed ID: 7798300
    [TBL] [Abstract][Full Text] [Related]  

  • 10. Correlations among p53, Her-2/neu, and ras overexpression and aneuploidy by multiparameter flow cytometry in human breast cancer: evidence for a common phenotypic evolutionary pattern in infiltrating ductal carcinomas.
    Smith CA; Pollice AA; Gu LP; Brown KA; Singh SG; Janocko LE; Johnson R; Julian T; Hyams D; Wolmark N; Sweeney L; Silverman JF; Shackney SE
    Clin Cancer Res; 2000 Jan; 6(1):112-26. PubMed ID: 10656439
    [TBL] [Abstract][Full Text] [Related]  

  • 11. Multivariate analysis of bcl-2, apoptosis, P53 and HER-2/neu in breast cancer: a short-term follow-up.
    el-Ahmady O; el-Salahy E; Mahmoud M; Wahab MA; Eissa S; Khalifa A
    Anticancer Res; 2002; 22(4):2493-9. PubMed ID: 12174951
    [TBL] [Abstract][Full Text] [Related]  

  • 12. Expression of cell regulatory proteins in ovarian borderline tumors.
    van Haaften-Day C; Russell P; Boyer CM; Kerns BJ; Wiener JR; Jensen DN; Bast RC; Hacker NF
    Cancer; 1996 May; 77(10):2092-8. PubMed ID: 8640675
    [TBL] [Abstract][Full Text] [Related]  

  • 13. HER-2/neu and p53 overexpression as biomarkers of breast carcinoma in women age 30 years and younger.
    Maru D; Middleton LP; Wang S; Valero V; Sahin A
    Cancer; 2005 Mar; 103(5):900-5. PubMed ID: 15643600
    [TBL] [Abstract][Full Text] [Related]  

  • 14. Expression of EGFR, HER-2/neu, P53, and PCNA in endometrioid, serous papillary, and clear cell endometrial adenocarcinomas.
    Khalifa MA; Mannel RS; Haraway SD; Walker J; Min KW
    Gynecol Oncol; 1994 Apr; 53(1):84-92. PubMed ID: 7909788
    [TBL] [Abstract][Full Text] [Related]  

  • 15. Immunohistochemical detection of p53 protein expression in breast cancer in young Kuwaiti women.
    Temmim L; Baker H; Sinowatz F
    Anticancer Res; 2001; 21(1B):743-8. PubMed ID: 11299837
    [TBL] [Abstract][Full Text] [Related]  

  • 16. Relationship between p53 and c-erbB-2 overexpression in tissue sections and cyst fluid cells of patients with ovarian cancer.
    Harłozińska A; Bar JK
    Tumour Biol; 1994; 15(4):223-9. PubMed ID: 7939171
    [TBL] [Abstract][Full Text] [Related]  

  • 17. HER-2/neu and p53 expression versus tamoxifen resistance in estrogen receptor-positive, node-positive breast cancer.
    Berry DA; Muss HB; Thor AD; Dressler L; Liu ET; Broadwater G; Budman DR; Henderson IC; Barcos M; Hayes D; Norton L
    J Clin Oncol; 2000 Oct; 18(20):3471-9. PubMed ID: 11032587
    [TBL] [Abstract][Full Text] [Related]  

  • 18. The DCC protein expression in breast carcinoma.
    Hsu YH; Shaw CK
    Kaohsiung J Med Sci; 2000 May; 16(5):233-40. PubMed ID: 10969518
    [TBL] [Abstract][Full Text] [Related]  

  • 19. Anti-Her-2/neu antibody induces apoptosis in Her-2/neu overexpressing breast cancer cells independently from p53 status.
    Brodowicz T; Kandioler D; Tomek S; Ludwig C; Rudas M; Kunstfeld R; Koestler W; Hejna M; Budinsky A; Wiltschke C; Zielinski CC
    Br J Cancer; 2001 Nov; 85(11):1764-70. PubMed ID: 11742500
    [TBL] [Abstract][Full Text] [Related]  

  • 20. HER-2/neu overexpression in breast cancer: an immunohistochemical study including correlations with clinicopathologic parameters, p53 oncoprotein and cathepsin-D.
    Korkolis D; Ardavanis A; Yotis J; Kyroudi A; Gorgoulis V; Kittas C
    Anticancer Res; 2001; 21(3C):2207-12. PubMed ID: 11501848
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 5.